Spring Issue of the MS Society with the following article:

 MAKING CHOICES:  MS, CCSVI AND YOU - Nardina, post CCSVI procedure

Today, people living with MS have more choices than ever before regarding the treatment and management of their symptoms.

Nardina, who chooses not to treat her MS using standard drug therapies, was excited when she heard about the CCSVI procedure and welcomed it as a possible option for helping her manage MS.  Chronic cerebrospinal venous insufficiency or CCSVI is a term used by Dr. Paolo Zamboni that suggests clogged veins can be a cause of MS.  He believes that unblocking the veins can have a positive effect on one's quality of life.

In November 2010, with hopes of decreasing the severity of her MS symptoms, Nardina traveled to Mexico to receive a CCSVI procedure.  "I fell often and worried one day I would fall down the stairs," she says about making the decision to go.  "When I heard about CCSVI I wanted the procedure done right away.  I needed to change my life."

Post-procedure, Nardina is pleased with the decision she made and reports several improvements to her MS symptoms.  She recognizes that not everyone has positive CCSVI-treatment results and supports the need for accelerated research like the MS Society of Canada's joint funding of seven CCSVI and MS research studies totaling $2.4 million with the U.S. National MS Society.  In addition, Nardina backs up any activities that could potentially fast-track CCSVI being available within the Canadian healthcare system as a treatment for MS and expressed appreciation for the MS Society`s commitment of $1 million for a clinical trial if research shows one is warranted.

To help you in making decisions about MS and CCSVI, the MS Society has created a web-based resource that offers up to date and accurate information on CCSVI and addresses the questions and concerns faced by those considering CCSVI-related procedures.  Please visit CCSVI.ca

The article begins with Nardina being pleased with her decision, needed to change her life, reports several improvements to her symptoms, yet expressed appreciation for the $1 million funding for a clinical trial if research shows one is warranted?  If research is warranted?  A contradiction coming from someone who was successfully treated for CCSVI?  Even when the MS newsletter finally begins to actually mention CCSVI in it's articles, it is done in a back-handed fashion.  

- Shirl